|Bid||0.0000 x N/A|
|Ask||0.0000 x N/A|
|Day's range||21.1810 - 22.0000|
|52-week range||21.1810 - 22.0000|
|Beta (5Y monthly)||0.67|
|PE ratio (TTM)||N/A|
|Earnings date||04 Aug 2021 - 09 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
On Anavex's (AVXL) earnings call for the fiscal third quarter, investor focus will mainly be on the company's progress with its lead investigational candidate for Alzheimer's disease.
Yahoo Finance's Myles Udland talks with Anavex Life Sciences CEO Christopher Missling about the company's new Parkinson's disease drugs as well as its recent capital-raising stock sale.